The nation of Zimbabwe has turned down a substantial US healthcare agreement worth 367 million US dollars (272 million pounds) spanning five years due to the United States' insistence on confidential data.
This rejection became public after a government memo from December was leaked, which showed President Emmerson Mnangagwa believed the arrangement was "unbalanced".
A government representative later stated that the United States was demanding access to genetic material for research and profit but refused to share the benefits from any future treatments.
"We will now turn to the difficult and regrettable task of winding down our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had donated over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has urged continued talks to secure a deal agreeable to both sides so the country's critical HIV programme can proceed.
Wider Context
This development follows a similar situation in neighbouring Kenya, where a court halted a related health funding agreement after concerns were raised about the security of citizens' health data.
Since resuming the presidency last year, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
The agency had managed aid for the US government, but Trump argued its spending was "inefficient" and his administration was pursuing government-to-government deals to enhance transparency and accountability.
As per reports, 16 African countries have to date signed these new agreements, constituting more than $18.3bn of fresh investment.
Specifics of the Declined Agreement
The money for Zimbabwe would have funded "tackling HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We believe this partnership would have delivered extraordinary advantages for the people of Zimbabwe, especially the 1.2 million men, women and children currently on HIV treatment via US-supported programmes," the Ambassador commented.
However, government spokesperson Nick Mangwana maintained the arrangement was "unequal".
"The proposal required Zimbabwe to share its biological resources and data over an extended period, without any equivalent promise of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might be developed from that provided information," Mangwana explained.
"Effectively, our country would supply the basic resources for medical research without any assurance that the final treatments would be accessible to our people should a new health crisis arise."
National Interest and Global Health
Mangwana further pointed out that the American exit from the World Health Organization (WHO) and its push of one-on-one deals were disrupting frameworks already established through the international health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing scheme designed to deal with future global health emergencies.
"This mechanism is designed to guarantee that when a country provides its data, the resulting advantages – including medicines and cures – are distributed fairly, not monopolised solely by those with the capability to create them."
Zimbabwe's reservations regarding the US deal "are not meant as opposition to America," Mangwana stressed.
"We are open to further dialogue with our US partners on how future collaboration might be designed in a manner that honours the sovereignty and interests of both nations."
Health Experts Response
Medical experts stated it recognised the government's concerns, but recommended that negotiations should continue considering a large portion of the nation's Aids initiatives depended on external financing.
"In cases where specific concerns arise, such as those relating to data governance or agreement terms, these can frequently be resolved via technical clarification and negotiated safeguards," the group commented.
The situation underscores the complex debate between accepting much-needed international aid and safeguarding a country's data in an ever more data-driven world.